Cti Biopharma Corp Stock Cash And Equivalents
| CTICDelisted Stock | USD 9.09 0.00 0.00% |
CTi Biopharma Corp fundamentals help investors to digest information that contributes to CTi Biopharma's financial success or failures. It also enables traders to predict the movement of CTi Stock. The fundamental analysis module provides a way to measure CTi Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CTi Biopharma stock.
CTi |
CTi Biopharma Corp Company Cash And Equivalents Analysis
CTi Biopharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current CTi Biopharma Cash And Equivalents | 81.64 M |
Most of CTi Biopharma's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CTi Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, CTi Biopharma Corp has 81.64 M in Cash And Equivalents. This is 90.05% lower than that of the Biotechnology sector and 81.74% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 96.98% higher than that of the company.
CTi Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CTi Biopharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CTi Biopharma could also be used in its relative valuation, which is a method of valuing CTi Biopharma by comparing valuation metrics of similar companies.CTi Biopharma is currently under evaluation in cash and equivalents category among its peers.
CTi Fundamentals
| Return On Equity | -10.19 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.91) % | |||
| Operating Margin | (0.74) % | |||
| Current Valuation | 1.26 B | |||
| Shares Outstanding | 131.88 M | |||
| Shares Owned By Insiders | 5.49 % | |||
| Shares Owned By Institutions | 83.28 % | |||
| Number Of Shares Shorted | 11.27 M | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 112.63 X | |||
| Price To Sales | 22.01 X | |||
| Revenue | 53.95 M | |||
| Gross Profit | 50.43 M | |||
| EBITDA | (79.85 M) | |||
| Net Income | (92.99 M) | |||
| Cash And Equivalents | 81.64 M | |||
| Cash Per Share | 0.64 X | |||
| Total Debt | 49.96 M | |||
| Current Ratio | 3.26 X | |||
| Book Value Per Share | (0.19) X | |||
| Cash Flow From Operations | (81.19 M) | |||
| Short Ratio | 1.08 X | |||
| Earnings Per Share | (0.54) X | |||
| Target Price | 10.05 | |||
| Number Of Employees | 127 | |||
| Beta | 0.83 | |||
| Market Capitalization | 1.2 B | |||
| Total Asset | 125.92 M | |||
| Retained Earnings | (2.52 B) | |||
| Working Capital | 18.26 M | |||
| Current Asset | 134.97 M | |||
| Current Liabilities | 72.41 M | |||
| Z Score | -15.1 | |||
| Net Asset | 125.92 M |
About CTi Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CTi Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CTi Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CTi Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in CTi Stock
If you are still planning to invest in CTi Biopharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CTi Biopharma's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |